Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 22;8(1):66-72.
doi: 10.1002/wjo2.10. eCollection 2022 Mar.

Exclusively endoscopic surgical resection of esthesioneuroblastoma: A systematic review

Daniel B Spielman  1 , Andi Liebowitz  1 , Maeher Grewal  1 , Chetan Safi  1 , Jonathan B Overdevest  1 , Alfred M Iloreta  2 , Brett E Youngerman  3 , David A Gudis  1
Affiliations
Review

Exclusively endoscopic surgical resection of esthesioneuroblastoma: A systematic review

Daniel B Spielman et al. World J Otorhinolaryngol Head Neck Surg. .

Abstract

Background: Historically sinonasal malignancies were always addressed via open craniofacial surgery for an oncologic resection. Increasingly esthesioneuroblastomas are excised using an exclusively endoscopic approach, however, the rarity of this disease limits the availability of long-term and large scale outcomes data.

Objective: The primary objective is to evaluate the treatment modalities used and the overall survival of patients with esthesioneuroblastoma managed with exclusively endoscopic surgery.

Methods: In accordance with PRISMA guidelines, PubMed was queried to identify studies describing outcomes associated with endoscopic management of esthesioneuroblastomas.

Results: Forty-four out of 2462 articles met inclusion criteria, totaling 399 patients with esthesioneuroblastoma treated with an exclusively endoscopic approach. Seventy-two patients (18.0%) received adjuvant chemotherapy and 331 patients (83.0%) received postoperative radiation therapy. The average age was 50.6 years old (range 6-83). Of the 399 patients, 57 (16.6%) were Kadish stage A, 121 (35.2%) were Kadish stage B, 145 (42.2%) were Kadish stage C, and 21 (6.1%) were Kadish stage D. Pooled analysis demonstrated that 66.0% of patients had Hyams histologic Grade Ⅰ or Ⅱ, while 34.0% of patients had Grade Ⅲ or Ⅳ disease. Negative surgical margins were achieved in 86.9% of patients, and recurrence was identified in 10.3% of patients. Of those with 5-year follow-up, reported overall survival was 91.1%.

Conclusion: Exclusively endoscopic surgery for esthesioneuroblastoma is performed for a wide range of disease stages and grades, and the majority of these patients are also treated with adjuvant chemotherapy or radiation therapy. Reported overall recurrence rate is 10.3% and 5-year survival is 91.1%.

Keywords: anterior skull base; endoscopic skull base surgery; esthesioneuroblastoma; olfactory neuroblastoma; skull base.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart of study selection
See this image and copyright information in PMC

References

    1. Clifford P. Transcranial approach for cancer of the antroethmoidal area. Clin Otolaryngol Allied Sci. 1977;2:115‐130. - PubMed
    1. Chapman P, Carter RL, Clifford P. The diagnosis and surgical management of olfactory neuroblastoma: the role of craniofacial resection. J Laryngol Otol. 1981;95:785‐799. - PubMed
    1. Devaiah AK, Larsen C, Tawfik O, O'Boynick P, Hoover LA. Esthesioneuroblastoma: endoscopic nasal and anterior craniotomy resection. Laryngoscope. 2003;113:2086‐2090. - PubMed
    1. Walch C, Stammberger H, Anderhuber W, Unger F, Köle W, Feichtinger K. The minimally invasive approach to olfactory neuroblastoma: combined endoscopic and stereotactic treatment. Laryngoscope. 2000;110:635‐640. - PubMed
    1. Dumont B, Fresneau B, Claude L, et al. Pattern of loco‐regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (Fracture) contribution. Pediatr Blood Cancer. 2020;67:e28154. - PubMed